查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089710

銀屑病治療市場規模、佔有率和趨勢分析報告：按藥物類別、療法、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

銀屑病治療市場概述

全球乾癬治療市場預計到 2025 年將達到 232.7 億美元，從 2026 年的 257 億美元成長到 2033 年的 548.8 億美元，2026 年至 2033 年的複合年成長率為 11.4%。

到2025年，北美銀屑病治療市場將佔全球市場的38.3%，成為最大的市場佔有率。銀屑病治療市場正呈現強勁成長勢頭，這主要得益於免疫調節劑的進步、生物製藥療法的日益普及以及發達醫療市場有利的保險報銷政策。

資料來源：Grand View Research、投資人關係資料、初步訪談、付費資料庫

持續的研發活動正在推動治療方法的創新，尤其是在中重度乾癬治療方面，從而支撐了對標靶治療的需求。市場的一個關鍵趨勢是生物相似藥競爭加劇，這正在重塑現有生物製藥的競爭格局，並改善患者獲得治療的機會。醫療專業人員和保險公司對生物相似藥的接受度不斷提高，有助於降低治療成本，並增加患者的用藥機會，尤其是在對成本敏感的市場。此外，市場正持續向先進的白細胞介素抑制劑和標靶口服療法轉型，與傳統全身療法相比，這些療法具有更高的療效、更長的治療持續時間和更佳的臨床結果。在對生物目標和新一代口服療法的日益青睞的推動下，市場也正朝著基於精準醫療的銀屑病管理模式發生顯著轉變。靶向IL-17和IL-23通路的白細胞介素抑制劑因其皮膚症狀緩解率高、起效迅速和治療反應持久而持續取得巨大的商業性成功。製藥公司正積極致力於生命週期管理策略、拓展適應症以及研發改良製劑，以鞏固其在競爭激烈的免疫學領域的市場地位。此外，醫生對長期疾病管理和減少合併症重要性的認知不斷提高，也促進了先進銀屑病療法的廣泛應用。

慢性發炎性皮膚病患病率的上升以及對長期疾病管理療法需求的不斷成長，持續推動著銀屑病治療市場的成長。與傳統療法相比，先進生物製藥和標靶治療的廣泛應用，顯著提高了療效，改善了症狀控制，並提升了患者預後，從而促進了該市場的發展。此外，醫療保健支出的增加、皮膚科專科診療服務的普及以及早期診斷和治療意識的提高，也進一步推動了市場擴張。持續的產品創新、生物相似藥的不斷湧現以及監管機構對新型銀屑病療法的持續支持，預計將在預測期內維持市場競爭態勢，並創造有利的成長機會。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：銀屑病治療市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：銀屑病治療市場：按藥物類別分類的業務分析

  • 按類別分類的市場佔有率（2025 年和 2033 年）
  • 2021年至2033年各類別市場規模、預測與趨勢分析
  • 腫瘤壞死因子抑制劑
  • 白細胞介素抑制劑
  • 維生素D類似物
  • 皮質類固醇
  • 其他

第5章：銀屑病治療市場：按療法分類的業務分析

  • 按治療方法分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療方法分類，2021-2033 年
  • 外用藥物
  • 全身性治療
  • 生物製劑

第6章：銀屑病治療市場：依給藥途徑分類的業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 口服
  • 腸外
  • 外用

第7章：銀屑病治療市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 其他藥房

第8章：銀屑病治療市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Eli Lilly And Company
    • Celgene Corporation
    • UCB SA
    • Merck
    • Boehringer Ingelheim International GmbH
Product Code: GVR-1-68038-662-2

Psoriasis Drugs Market Summary

The global psoriasis drugs market size was valued at USD 23.27 billion in 2025 and is projected to grow from USD 25.70 billion in 2026 to USD 54.88 billion by 2033, at a CAGR of 11.4% from 2026 to 2033. North America psoriasis drugs market held the largest share of 38.3% of the global market in 2025. The psoriasis drugs market is witnessing strong growth driven by advances in immunomodulators, increasing adoption of biologic therapies, and favorable reimbursement support across developed healthcare markets.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

Continuous research and development activities are contributing to treatment innovation, particularly for moderate to severe psoriasis cases, thereby supporting demand for targeted therapies. A major market trend is the increasing competition from biosimilars, which is reshaping the competitive landscape for established biologics and improving treatment accessibility. Growing acceptance of biosimilars among healthcare providers and payers is helping reduce herapy costs and expand patient access, especially in cost-sensitive markets. In addition, the market continues to shift toward advanced interleukin inhibitors and targeted oral therapies due to their improved efficacy, longer treatment durability, and favorable clinical outcomes compared to conventional systemic treatments.The market is also experiencing a strong shift toward precision-based psoriasis management, supported by the increasing preference for targeted biologics and next-generation oral therapies. Interleukin inhibitors targeting IL-17 and IL-23 pathways continue to gain significant commercial traction due to their high skin clearance rates, rapid onset of action, and sustained therapeutic response. Pharmaceutical companies are actively focusing on lifecycle management strategies, label expansions, and development of improved formulations to strengthen product positioning in the competitive immunology segment. In addition, increasing physician awareness regarding long-term disease management and comorbidity reduction is contributing to higher adoption of advanced psoriasis therapeutics.

Rising prevalence of chronic inflammatory skin disorders and increasing demand for long-term disease management therapies continue to support the growth of the psoriasis drugs market. The market is benefiting from higher adoption of advanced biologics and targeted therapies that offer improved efficacy, better symptom control, and enhanced patient outcomes compared to conventional treatments. In addition, increasing healthcare expenditure, expanding access to specialty dermatology care, and growing awareness regarding early diagnosis and treatment are further contributing to market expansion. Continuous product innovation, broader biosimilar availability, and ongoing regulatory support for novel psoriasis therapies are expected to sustain competitive development and create favorable growth opportunities for the market during the forecast period.

Global Psoriasis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region:

  • Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tumor Necrosis Factor Inhibitors
  • Interleukin Inhibitors
  • Vitamin D Analogues
  • Corticosteroids
  • Others
  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
  • Topicals
  • Systemic
  • Biologics
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Parenteral
  • Topical
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Pharmacies
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drugs Market: Class Business Analysis

  • 4.1. Class Market Share, 2025 & 2033
  • 4.2. Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2021 to 2033 (USD Billion)
  • 4.4. Tumor Necrosis Factor Inhibitors
    • 4.4.1. Tumor Necrosis Factor Inhibitors Market, 2021 - 2033 (USD Billion)
  • 4.5. Interleukin Inhibitors
    • 4.5.1. Interleukin Inhibitors Market, 2021 - 2033 (USD Billion)
  • 4.6. Vitamin D Analogues
    • 4.6.1. Vitamin D Analogues Market, 2021 - 2033 (USD Billion)
  • 4.7. Corticosteroids
    • 4.7.1. Corticosteroids Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Psoriasis Drugs Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
  • 5.4. Topicals
    • 5.4.1. Topicals Market, 2021 - 2033 (USD Billion)
  • 5.5. Systemic
    • 5.5.1. Systemic Market, 2021 - 2033 (USD Billion)
  • 5.6. Biologics
    • 5.6.1. Biologics Market, 2021 - 2033 (USD Billion)

Chapter 6. Psoriasis Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
  • 6.5. Parenteral
    • 6.5.1. Parenteral Market, 2021 - 2033 (USD Billion)
  • 6.6. Topical
    • 6.6.1. Topical Market, 2021 - 2033 (USD Billion)

Chapter 7. Psoriasis Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Psoriasis Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 8.4. North America
    • 8.4.1. North America Psoriasis Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Amgen Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Johnson & Johnson Services, Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Novartis AG
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Eli Lilly And Company
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Celgene Corporation
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. UCB S.A.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Merck
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Boehringer Ingelheim International GmbH
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global psoriasis drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 5 Global psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 6 Global psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 7 Global psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 10 North America psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 11 North America psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 12 North America psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 U.S psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 14 U.S psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 15 U.S psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 16 U.S psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 18 Canada psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 19 Canada psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 20 Canada psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 22 Mexico psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 23 Mexico psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 24 Mexico psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 27 Europe psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 28 Europe psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 29 Europe psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 31 UK psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 32 UK psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 33 UK psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 35 Germany psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 36 Germany psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 37 Germany psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 39 France psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 40 France psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 41 France psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 43 Italy psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 44 Italy psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 45 Italy psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 47 Spain psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 48 Spain psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 49 Spain psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 51 Norway psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 52 Norway psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 53 Norway psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 55 Denmark psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 56 Denmark psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 57 Denmark psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 59 Sweden psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 60 Sweden psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 61 Sweden psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 68 Japan psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 69 Japan psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 70 Japan psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 72 China psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 73 China psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 74 China psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 76 India psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 77 India psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 78 India psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 80 Australia psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 81 Australia psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 82 Australia psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 84 South Korea psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 85 South Korea psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 86 South Korea psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 88 Thailand psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 89 Thailand psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 90 Thailand psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 93 Latin America psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 94 Latin America psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 95 Latin America psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 97 Brazil psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 98 Brazil psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 99 Brazil psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 101 Argentina psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 102 Argentina psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 103 Argentina psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa psoriasis drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 110 South Africa psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 111 South Africa psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 112 South Africa psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 118 UAE psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 119 UAE psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 120 UAE psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait psoriasis drugs market, by class, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait psoriasis drugs market, by treatment, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait psoriasis drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait psoriasis drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Psoriasis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Psoriasis drugs market dynamics
  • Fig. 11 Psoriasis drugs market: Porter's five forces analysis
  • Fig. 12 Psoriasis drugs market: PESTLE analysis
  • Fig. 13 Class market, 2021 - 2033 (USD Billion)
  • Fig. 14 Tumor necrosis factor inhibitors market, 2021 - 2033 (USD Billion)
  • Fig. 15 Interleukin inhibitors market, 2021 - 2033 (USD Billion)
  • Fig. 16 Vitamin D analogues market, 2021 - 2033 (USD Billion)
  • Fig. 17 Corticosteroids market, 2021 - 2033 (USD Billion)
  • Fig. 18 Others market, 2021 - 2033 (USD Billion)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Billion)
  • Fig. 20 Topicals market, 2021 - 2033 (USD Billion)
  • Fig. 21 Systemic market, 2021 - 2033 (USD Billion)
  • Fig. 22 Biologics market, 2021 - 2033 (USD Billion)
  • Fig. 23 Route of administration market, 2021 - 2033 (USD Billion)
  • Fig. 24 Oral market, 2021 - 2033 (USD Billion)
  • Fig. 25 Parenteral market, 2021 - 2033 (USD Billion)
  • Fig. 26 Topical market, 2021 - 2033 (USD Billion)
  • Fig. 27 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 29 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 30 Other pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 31 Psoriasis drugs market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait Psoriasis drugs market, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework